XML 127 R34.htm IDEA: XBRL DOCUMENT
v2.4.0.8

Quarterly Financial Data (Unaudited) | 12 Months Ended
--- | ---
Dec. 31, 2013
Quarterly Financial Information Disclosure [Abstract] |
Quarterly Financial Data (Unaudited) |
| Quarterly Financial Data (Unaudited)
(In millions, except per share amounts) | First Quarter |  | Second Quarter |  | Third Quarter |  | Fourth Quarter |  | Total Year
2013 | (a) |  | (b) |  | (b) (c) |  | (b) |  |
Product revenues | $ | 1,095.8 |  |  | $ | 1,385.9 |  |  | $ | 1,453.6 |  |  | $ | 1,607.1 |  |  | $ | 5,542.3 |
Unconsolidated joint business revenues | $ | 264.6 |  |  | $ | 288.8 |  |  | $ | 303.2 |  |  | $ | 269.4 |  |  | $ | 1,126.0 |
Other revenues | $ | 54.7 |  |  | $ | 48.8 |  |  | $ | 71.0 |  |  | $ | 89.4 |  |  | $ | 263.9 |
Total revenues | $ | 1,415.1 |  |  | $ | 1,723.5 |  |  | $ | 1,827.8 |  |  | $ | 1,965.9 |  |  | $ | 6,932.2 |
Gross profit | $ | 1,281.4 |  |  | $ | 1,492.8 |  |  | $ | 1,593.1 |  |  | $ | 1,707.3 |  |  | $ | 6,074.5 |
Net income | $ | 426.7 |  |  | $ | 490.7 |  |  | $ | 487.6 |  |  | $ | 457.3 |  |  | $ | 1,862.3 |
Net income attributable to Biogen Idec Inc. | $ | 426.7 |  |  | $ | 490.7 |  |  | $ | 487.6 |  |  | $ | 457.3 |  |  | $ | 1,862.3 |
Basic earnings per share attributable to Biogen Idec Inc. | $ | 1.80 |  |  | $ | 2.07 |  |  | $ | 2.06 |  |  | $ | 1.94 |  |  | $ | 7.86 |
Diluted earnings per share attributable to Biogen Idec Inc. | $ | 1.79 |  |  | $ | 2.06 |  |  | $ | 2.05 |  |  | $ | 1.92 |  |  | $ | 7.81 |
(In millions, except per share amounts) | First Quarter |  | Second Quarter |  | Third Quarter |  | Fourth Quarter |  | Total Year
2012 | (d) |  |  |  |  |  | (e) (f) |  |
Product revenues | $ | 975.4 |  |  | $ | 1,076.8 |  |  | $ | 1,039.1 |  |  | $ | 1,074.7 |  |  | $ | 4,166.1 |
Unconsolidated joint business revenues | $ | 284.6 |  |  | $ | 284.6 |  |  | $ | 287.8 |  |  | $ | 280.9 |  |  | $ | 1,137.9 |
Other revenues | $ | 32.0 |  |  | $ | 59.6 |  |  | $ | 58.6 |  |  | $ | 62.3 |  |  | $ | 212.5 |
Total revenues | $ | 1,292.0 |  |  | $ | 1,421.0 |  |  | $ | 1,385.5 |  |  | $ | 1,417.9 |  |  | $ | 5,516.5 |
Gross profit | $ | 1,158.8 |  |  | $ | 1,281.8 |  |  | $ | 1,246.2 |  |  | $ | 1,284.1 |  |  | $ | 4,971.0 |
Net income | $ | 302.4 |  |  | $ | 387.1 |  |  | $ | 398.4 |  |  | $ | 292.1 |  |  | $ | 1,380.0 |
Net income attributable to Biogen Idec Inc. | $ | 302.7 |  |  | $ | 386.8 |  |  | $ | 398.4 |  |  | $ | 292.1 |  |  | $ | 1,380.0 |
Basic earnings per share attributable to Biogen Idec Inc. | $ | 1.26 |  |  | $ | 1.62 |  |  | $ | 1.68 |  |  | $ | 1.24 |  |  | $ | 5.80 |
Diluted earnings per share attributable to Biogen Idec Inc. | $ | 1.25 |  |  | $ | 1.61 |  |  | $ | 1.67 |  |  | $ | 1.23 |  |  | $ | 5.76 |
Full year amounts may not sum due to rounding.
(a) | Our share of revenues from unconsolidated joint business reflects a charge of $41.5 million for damages and interest awarded to Hoechst in Genentech's arbitration with Hoechst for RITUXAN.
(b) | Product revenues and total revenues for the second, third and fourth quarters of 2013 includes 100% of net revenues related to sales of TYSABRI as a result of our acquisition of TYSABRI rights from Elan on April 2, 2013 and net revenues related to sales of TECFIDERA, our new oral first-line treatment for people with relapsing forms of multiple sclerosis (MS), which was approved by the FDA in March 2013 and commenced commercial sales in April 2013.
(c) | Net income and net income attributable to Biogen Idec Inc., for the third quarter of 2013, includes a charge to research and development expense of $75.0 million related to an upfront payment made in connection with our collaboration agreement entered into with Isis.
(d) | Net income and net income attributable to Biogen Idec Inc. for the first quarter of 2012 includes a charge to research and development expense of $29.0 million related to an upfront payment made in connection with our development agreement entered into with Isis.
(e) | Net income and net income attributable to Biogen Idec Inc. for the fourth quarter of 2012 includes the correction of an error that had accumulated over several prior years in our deferred tax accounting for capitalized interest which resulted in an expense of $29.0 million.
(f) | Net income and net income attributable to Biogen Idec Inc. for the fourth quarter of 2012 includes a charge to research and development expense of $30.0 million related to an upfront payment made in connection with our development agreement entered into with Isis.

X
- Details
Name: | us-gaap_QuarterlyFinancialInformationDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for the quarterly financial data in the annual financial statements. The disclosure may include a tabular presentation of financial information for each fiscal quarter for the current and previous year, including revenues, gross profit, income or loss before extraordinary items and earnings per share data. It also includes an indication if the information in the note is unaudited, comments on the aggregate effect of year-end adjustments, and an explanation of matters or transactions that affect comparability or are pertinent to an understanding of the information furnished. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 270 -SubTopic 10 -Section 45 -Paragraph 13 -URI http://asc.fasb.org/extlink&oid=6372559&loc=d3e765-108305 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 270 -SubTopic 10 -Section 45 -Paragraph 12 -URI http://asc.fasb.org/extlink&oid=6372559&loc=d3e725-108305 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 270 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a)-(j) -URI http://asc.fasb.org/extlink&oid=25249566&loc=d3e1280-108306 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 6 -Section G -Subsection 1 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K (SK) -Number 229 -Section 302 -Paragraph a + Details
Name: | us-gaap_QuarterlyFinancialInformationTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration